FGF21 and metabolic syndrome: A third trial, a phase 1 multiple ascending dose study in individuals with T2D (NCT01856881), tested AKR-001, an Fc-FGF21 analog harboring stabilized N- and C-terminal domains of FGF21, resulting in improved serum markers for insulin sensitivity and dyslipidemia, and demonstrated trends toward improvements in glycemic control through enhancing insulin sensitivity under fasting and fed conditions [248].